Invenomic Capital Management LP raised its position in American Vanguard Co. (NYSE:AVD – Free Report) by 256.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 876,708 shares of the basic materials company’s stock after buying an additional 631,070 shares during the quarter. Invenomic Capital Management LP owned 3.05% of American Vanguard worth $9,617,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in American Vanguard by 492.4% in the 4th quarter. CWM LLC now owns 2,340 shares of the basic materials company’s stock valued at $26,000 after buying an additional 1,945 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of American Vanguard during the 4th quarter valued at $37,000. Tower Research Capital LLC TRC lifted its position in shares of American Vanguard by 240.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,885 shares of the basic materials company’s stock valued at $76,000 after acquiring an additional 4,863 shares during the period. Bfsg LLC bought a new stake in shares of American Vanguard during the 4th quarter valued at $98,000. Finally, WINTON GROUP Ltd bought a new stake in shares of American Vanguard during the 3rd quarter valued at $119,000. 79.04% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Steven D. Macicek purchased 8,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $9.01 per share, with a total value of $76,585.00. Following the completion of the purchase, the director now owns 10,044 shares in the company, valued at approximately $90,496.44. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Steven D. Macicek purchased 8,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $9.01 per share, with a total value of $76,585.00. Following the completion of the purchase, the director now owns 10,044 shares in the company, valued at approximately $90,496.44. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ulrich Trogele purchased 18,200 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average cost of $8.75 per share, with a total value of $159,250.00. Following the purchase, the insider now owns 209,876 shares of the company’s stock, valued at approximately $1,836,415. The disclosure for this purchase can be found here. Insiders own 10.10% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on American Vanguard
American Vanguard Trading Down 0.7 %
American Vanguard stock traded down $0.06 during trading hours on Monday, hitting $8.61. The stock had a trading volume of 85,565 shares, compared to its average volume of 217,134. The company has a quick ratio of 1.12, a current ratio of 2.29 and a debt-to-equity ratio of 0.50. The stock has a market cap of $240.99 million, a price-to-earnings ratio of 32.85 and a beta of 0.95. American Vanguard Co. has a one year low of $8.41 and a one year high of $18.31. The business’s 50 day simple moving average is $10.62 and its 200-day simple moving average is $10.74.
American Vanguard (NYSE:AVD – Get Free Report) last posted its earnings results on Thursday, May 9th. The basic materials company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.08 by $0.01. The firm had revenue of $135.14 million during the quarter, compared to the consensus estimate of $141.20 million. American Vanguard had a return on equity of 2.20% and a net margin of 1.22%. During the same period last year, the company earned $0.07 earnings per share. On average, equities analysts predict that American Vanguard Co. will post 0.44 EPS for the current fiscal year.
About American Vanguard
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, including insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, soil fumigants, and biorationals in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection.
Recommended Stories
- Five stocks we like better than American Vanguard
- Investing In Automotive Stocks
- Autodesk Raises Guidance After Clearing Audit Investigation
- Stock Market Sectors: What Are They and How Many Are There?
- Lyft Stock Gap and Craps on Bold 2027 Guidance at Investor Day
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- How HP Stock Could Bring Double-Digit Upside for Buffett
Receive News & Ratings for American Vanguard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Vanguard and related companies with MarketBeat.com's FREE daily email newsletter.